<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735345</url>
  </required_header>
  <id_info>
    <org_study_id>AGMT_ECa</org_study_id>
    <secondary_id>EudraCT Nr. 2008-001016-21</secondary_id>
    <nct_id>NCT00735345</nct_id>
  </id_info>
  <brief_title>Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma</brief_title>
  <official_title>Chemotherapy Induction and Chemoradiotherapy Combined With Cetuximab Respectively in Patients With Non-Metastatic Esophageal Carcinoma: A Multicentric Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbeitsgemeinschaft medikamentoese Tumortherapie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Arbeitsgemeinschaft medikamentoese Tumortherapie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is the evaluate the feasibility and safety of chemotherapy induction
      treatment combined with cetuximab followed by chemoradiotherapy combined with cetuximab in
      the treatment of patients with non-metastatic esophageal cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with a locoregional carcinoma of the esophagus or gastro-esophageal junction have a
      low survival prognosis following surgical resection. In studies published to date no positive
      effect upon overall survival could be demonstrated for preoperative chemotherapy or
      chemoradiotherapy. However, patients with a complete remission following preoperative therapy
      show prolonged survival.

      This study design is based upon decreasing primary tumour and preventing oder delaying
      micrometastases by means of a chemo induction therapy, increasing R0 resection rates and
      preventing local recurrence by means of preoperative chemoradiotherapy, increasing the
      radiosensitivity of tumour cells through treatment combination with cetuximab, surgical
      resection of the locoregional primary tumour or definitive radiochemotherapy in case the
      primary tumour is inoperable.

      The aim of this study is therefore to evaluate the feasibility and safety of a 3-staged
      therapy approach including an EGFR antibody in the treatment of patients with potentially
      resectable esophageal cancer, as well as the evaluation of objective response rates to this
      preoperative therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    because of safety concerns the study was terminated prematurely
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of complete remissions and resection rate</measure>
    <time_frame>Duration of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of toxicities</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Quality of Life</measure>
    <time_frame>Duration of study</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemo induction therapy followed by chemoradiotherapy and surgical resection or definitive radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>15 mg/m2/d i.v. d1-5, d29-33</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Docetaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation during chemoradio-immunotherapy</intervention_name>
    <description>39.6 Gy total dose</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  histologically confirmed esophageal cancer (squamous cell carcinoma)

          -  measurable, non-metastatic disease (uT1-4)

          -  no previous cancer therapy (chemotherapy, radiotherapy or resection)

          -  life expectancy &gt; 3 months

          -  age &gt; 18 years

          -  WHO Status ≤ 2

          -  negative pregnancy test for women of child-bearing potential, and use of adequate
             contraception

          -  hematological status: neutrophiles ≥ 1,5x10E9/L, thrombocytes ≥ 100x10E9/L

          -  adequate renal function: serum creatinine ≤ 1,5 x ULN

          -  adequate liver function: alkaline phosphatase &lt; 2,5 x ULN, total bilirubin &lt; 1,5 x ULN

        Exclusion Criteria:

          -  pregnant or nursing women

          -  women of child-bearing potential without adequate contraception

          -  concomitant anti-tumoral therapy except study mandated procedures

          -  cervical esophageal cancer or diagnosis of metastases

          -  participation in other clinical trials within the last 30 days

          -  history of malignant disease within the last 5 years

          -  peripheral neuropathy (NCI CTC ≥ grade 1)

          -  concurrent active and serious non-malignant diseases: uncontrolled heart
             insufficiency, angina pectoris, hypertension or arrhythmias, liver disease,
             significant neurological or psychiatric conditions

          -  active infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Eisterer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universitaet Innsbruck</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Landeskrankenhaus Feldkirch</name>
      <address>
        <city>Feldkirch</city>
        <zip>A-6806</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>A-6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.ö. Landeskrankenhaus Leoben</name>
      <address>
        <city>Leoben</city>
        <zip>A-8700</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik f. Innere Medizin III</name>
      <address>
        <city>Salzburg</city>
        <zip>A-5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brueder St. Veit a.d. Glan</name>
      <address>
        <city>St. Veit/ Glan</city>
        <zip>A-9300</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Kreuzschwestern Wels GmbH</name>
      <address>
        <city>Wels</city>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>March 6, 2015</last_update_submitted>
  <last_update_submitted_qc>March 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2015</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Richard Greil</name_title>
    <organization>Arbeitsgemeinschaft medikamentoese Tumortherapie</organization>
  </responsible_party>
  <keyword>Esophageal cancer</keyword>
  <keyword>Pre-operative</keyword>
  <keyword>Chemo-immunotherapy</keyword>
  <keyword>Radiochemo-immunotherapy</keyword>
  <keyword>EGFR</keyword>
  <keyword>Radiosensitivity</keyword>
  <keyword>Resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

